A new biomarker for Alzheimer’s disease217 views
Recently researchers have discovered that a protein, the stages of which can be effortlessly examined in regular blood checkups, could provide as an innovative biomarker for Alzheimer’s disease, which gradually demolishes memory and thinking skills.
An international team of researchers evaluates the ranks of activity-dependent neuroprotective protein (ADNP) in elderly individuals at danger for Alzheimer’s disease, for the research study. Illana Gozes from Tel Aviv University in Israel, who is a lead researcher in the study, stated that “We have found a clear connection between ADNP levels in the blood and amyloid plaques — a hallmark Alzheimer’s — in the brain,”
The research study also discovered that ADNP stages examined in the blood connect with higher IQ in healthy older adults.
The consequences, cited in the Journal of Alzheimer’s Disease, propose that a regular blood analysis can disclose Alzheimer’s peril and IQ measurements. At present, the medical professionals have to perform an extensive series of experiments to evaluate a patient’s memory destruction and cognitive skills, functional aptitude and behavioral alterations to exactly detect Alzheimer’s disease.
For the goal of the research study, the researchers analyzed blood samples taken from 42 healthy adults, patients with mild cognitive impairment (MCI) and Alzheimer’s disease patients at Rambam Medical Center in Israel.
Importantly amplifies in ADNP RNA stages were examined in patients ranging from mild cognitive impairment to Alzheimer’s dementia.
Gozes stated that “This study has provided the basis to detect this biomarker in routine, non-invasive blood tests, and it is known that early intervention is invaluable to Alzheimer’s patients,” Gozes further pointed out that “We are now planning to take these preliminary findings forward into clinical trials to create a pre-Alzheimer’s test that will help to tailor potential preventative treatments,”